Skip to main content
Erschienen in: Die Urologie 7/2021

28.06.2021 | Hodentumoren | Leitthema

Management von Nebenwirkungen der Chemotherapie und deren Langzeitfolgen

verfasst von: Dr. med. Isabella M. Zraik, Dr. med. Yasmine Heß-Busch

Erschienen in: Die Urologie | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zur Behandlung von Hodentumoren werden verschiedene Chemotherapien verwendet. Die häufigsten Therapieregime sind PEB (Cisplatin, Etoposid, Bleomycin), Carboplatin Monotherapie (AUC 7), PEI (Cisplatin, Etoposid, Ifosfamid), TIP (Cisplatin, Ifosfamid, Paclitaxel) und GOP (Gemcitabin, Oxaliplatin, Paclitaxel). Hiermit gehen verschiedene Akut- und Spättoxizitäten einher. Hierzu zählen allgemeine Nebenwirkungen wie Anämie, Neutropenie, Übelkeit, Erbrechen, Durchfälle, Mukositis oder auch Paravasate sowie spezielle Toxizitäten wie Ototoxizität, Nephrotoxizität, pulmonale Toxizität, Neurotoxizität oder das Raynaud-Syndrom. Da in der Regel junge Männer betroffen sind, sind gerade auch die möglichen Langzeitfolgen wie Hypogonadismus, Infertilität oder das metabolische Syndrom sehr relevant. Dementsprechend ist ein adäquates Management der möglichen Nebenwirkungen und Langzeitfolgen im Rahmen des Einsatzes von Chemotherapien essentiell.
Literatur
1.
Zurück zum Zitat Aapro M, Saad F (2012) Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Ther Adv Urol 4:85–10PubMedPubMedCentralCrossRef Aapro M, Saad F (2012) Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Ther Adv Urol 4:85–10PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Abu Zaid M, Dinh PC, Monahan PO (2019) Adverse health outcomes in relationship to hypogonadism after chemotherapy: a multicenter study of testicular cancer survivors. J Natl Compr Canc Netw 17(5):459–468PubMedPubMedCentralCrossRef Abu Zaid M, Dinh PC, Monahan PO (2019) Adverse health outcomes in relationship to hypogonadism after chemotherapy: a multicenter study of testicular cancer survivors. J Natl Compr Canc Netw 17(5):459–468PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Adams SC, DeLorey DS, Davenport et al (2018) Effects of high-intensity interval training on fatigue and qualityof life in testicular cancer survivors. Br J Cancer 118:1313–1321PubMedPubMedCentralCrossRef Adams SC, DeLorey DS, Davenport et al (2018) Effects of high-intensity interval training on fatigue and qualityof life in testicular cancer survivors. Br J Cancer 118:1313–1321PubMedPubMedCentralCrossRef
4.
5.
Zurück zum Zitat Alkhateeb AA, Connor JR (2013) The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta 1836:245–254PubMed Alkhateeb AA, Connor JR (2013) The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta 1836:245–254PubMed
6.
Zurück zum Zitat Auerbach M, Silberstein PT, Webb RT et al (2010) Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 85:655–663PubMedCrossRef Auerbach M, Silberstein PT, Webb RT et al (2010) Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 85:655–663PubMedCrossRef
7.
Zurück zum Zitat Bandak M et al (2017) A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention). Bmc Cancer 17:461PubMedPubMedCentralCrossRef Bandak M et al (2017) A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention). Bmc Cancer 17:461PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Boer H, Proost JH, Nuver J et al (2015) Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. Ann Oncol 26:2305–2310PubMedPubMedCentralCrossRef Boer H, Proost JH, Nuver J et al (2015) Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. Ann Oncol 26:2305–2310PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Bogefors C et al (2017) Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome. Andrology 5:711PubMedCrossRef Bogefors C et al (2017) Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome. Andrology 5:711PubMedCrossRef
10.
Zurück zum Zitat Brydøy M, Oldenburg J, Klepp O et al (2009) Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101:1682–1695PubMedPubMedCentralCrossRef Brydøy M, Oldenburg J, Klepp O et al (2009) Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101:1682–1695PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Cella D, Kallich J, Mcdermott A et al (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 15:979–986PubMedCrossRef Cella D, Kallich J, Mcdermott A et al (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 15:979–986PubMedCrossRef
12.
13.
Zurück zum Zitat Daugaard G, Skoneczna I, Aass N et al (2011) A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 22:1054–1061PubMedCrossRef Daugaard G, Skoneczna I, Aass N et al (2011) A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 22:1054–1061PubMedCrossRef
14.
Zurück zum Zitat De Haas EC, Altena R, Boezen HM et al (2013) Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 24:749–755PubMedCrossRef De Haas EC, Altena R, Boezen HM et al (2013) Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 24:749–755PubMedCrossRef
15.
Zurück zum Zitat Dodd MJ, Larson PJ, Dibble SL et al (1996) Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 23:921–927PubMed Dodd MJ, Larson PJ, Dibble SL et al (1996) Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 23:921–927PubMed
16.
Zurück zum Zitat Dodd MJ, Miaskowski C, Greenspan D et al (2003) Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate versus salt & soda mouthwashes. Cancer Invest 21:21–33PubMedCrossRef Dodd MJ, Miaskowski C, Greenspan D et al (2003) Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate versus salt & soda mouthwashes. Cancer Invest 21:21–33PubMedCrossRef
17.
Zurück zum Zitat Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S (2018) EAU-Leitlinie Männlicher Hypogonadismus. J Reproduktionsmed Endokrinol_Online 15(2):71–88 Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S (2018) EAU-Leitlinie Männlicher Hypogonadismus. J Reproduktionsmed Endokrinol_Online 15(2):71–88
18.
Zurück zum Zitat Dolan ME, El Charif O, Wheeler HE et al (2017) Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer. Clin Cancer Res 23:5757–5768PubMedPubMedCentralCrossRef Dolan ME, El Charif O, Wheeler HE et al (2017) Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer. Clin Cancer Res 23:5757–5768PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Einhorn LH, Rapoport B, Navari RM et al (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303–308PubMedCrossRef Einhorn LH, Rapoport B, Navari RM et al (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303–308PubMedCrossRef
20.
Zurück zum Zitat Fallon MT, Storey DJ, Krishan A et al (2015) Cancer treatment-related neuropathic pain: proof of concept study with menthol—a TRPM8 agonist. Support Care Cancer 23:2769–2777PubMedPubMedCentralCrossRef Fallon MT, Storey DJ, Krishan A et al (2015) Cancer treatment-related neuropathic pain: proof of concept study with menthol—a TRPM8 agonist. Support Care Cancer 23:2769–2777PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Feldman DR, Schaffer WL, Steingart RM (2012) Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Canc Netw 10:537–544PubMedCrossRef Feldman DR, Schaffer WL, Steingart RM (2012) Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Canc Netw 10:537–544PubMedCrossRef
23.
Zurück zum Zitat Flechtner HH et al (2016) Quality-of-life analysis of the German prospective multicentre trial of single-cycle adjuvant BEP versus retroperitoneal lymph node dissection in clinical stage I Nonseminomatous germ cell tumours. Eur Urol 69:518PubMedCrossRef Flechtner HH et al (2016) Quality-of-life analysis of the German prospective multicentre trial of single-cycle adjuvant BEP versus retroperitoneal lymph node dissection in clinical stage I Nonseminomatous germ cell tumours. Eur Urol 69:518PubMedCrossRef
24.
Zurück zum Zitat Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, Storm H, Hall P, Holowaty E, Andersen A, Joensuu H, Andersson M, Kaijser M, Gospodarowicz M, Cohen R, Pukkala E, Travis LB (2007) Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 99(7):533–544PubMedCrossRef Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, Storm H, Hall P, Holowaty E, Andersen A, Joensuu H, Andersson M, Kaijser M, Gospodarowicz M, Cohen R, Pukkala E, Travis LB (2007) Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 99(7):533–544PubMedCrossRef
25.
Zurück zum Zitat Fung C, Fossa SD, Milano MT et al (2013) Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 31:3807–3814PubMedPubMedCentralCrossRef Fung C, Fossa SD, Milano MT et al (2013) Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 31:3807–3814PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Fung C, Fossa SD, Milano MT, Sahasrabudhe DM et al (2015) Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population based study. J Clin Oncol 33:3105–3115PubMedPubMedCentralCrossRef Fung C, Fossa SD, Milano MT, Sahasrabudhe DM et al (2015) Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population based study. J Clin Oncol 33:3105–3115PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Green DM, Liu W, Kutteh WH et al (2014) Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncol 15:1215–1223PubMedPubMedCentralCrossRef Green DM, Liu W, Kutteh WH et al (2014) Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncol 15:1215–1223PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Haugnes HS, Aass N, Fossa SD et al (2007) Components of the metabolic syndrome in long term survivors of testicular cancer. Ann Oncol 18:241–248PubMedCrossRef Haugnes HS, Aass N, Fossa SD et al (2007) Components of the metabolic syndrome in long term survivors of testicular cancer. Ann Oncol 18:241–248PubMedCrossRef
29.
Zurück zum Zitat Haugnes HS, Aass N, Fossa SD et al (2009) Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 27:2779–2786PubMedCrossRef Haugnes HS, Aass N, Fossa SD et al (2009) Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 27:2779–2786PubMedCrossRef
30.
Zurück zum Zitat Haugnes HS, Wethal T, Aass N et al (2010) Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 28:4649–4657PubMedCrossRef Haugnes HS, Wethal T, Aass N et al (2010) Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 28:4649–4657PubMedCrossRef
31.
Zurück zum Zitat Haugnes HS, Stenklev NC, Brydøy M et al (2018) Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. Acta Oncol 57:1075–1083PubMedCrossRef Haugnes HS, Stenklev NC, Brydøy M et al (2018) Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. Acta Oncol 57:1075–1083PubMedCrossRef
32.
Zurück zum Zitat Hjelle LV, Bremnes RM, Gundersen POM et al (2016) Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors. Urol Oncol 34:487.e413–487.e420CrossRef Hjelle LV, Bremnes RM, Gundersen POM et al (2016) Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors. Urol Oncol 34:487.e413–487.e420CrossRef
33.
Zurück zum Zitat Howard R et al (2008) Risk of leukemia among survivors of testicular cancer: a population based study of 42,722 patients. Ann Epidemiol 18:416PubMedPubMedCentralCrossRef Howard R et al (2008) Risk of leukemia among survivors of testicular cancer: a population based study of 42,722 patients. Ann Epidemiol 18:416PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Huddart RA, Norman A, Shahidi M et al (2003) Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513–1523PubMedCrossRef Huddart RA, Norman A, Shahidi M et al (2003) Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513–1523PubMedCrossRef
35.
Zurück zum Zitat Hwang MS, Lee HY, Choi TY et al (2020) A systematic review and meta-analysis of the efficacy of acupuncture and electroacupuncture against chemotherapy-induced peripheral neuropathy. Medicine 99:e19837PubMedPubMedCentralCrossRef Hwang MS, Lee HY, Choi TY et al (2020) A systematic review and meta-analysis of the efficacy of acupuncture and electroacupuncture against chemotherapy-induced peripheral neuropathy. Medicine 99:e19837PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Lampe H, Horwich A, Norman A et al (1997) Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 15:239–245PubMedCrossRef Lampe H, Horwich A, Norman A et al (1997) Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 15:239–245PubMedCrossRef
38.
Zurück zum Zitat Lauritsen J et al (2016) Pulmonary function in patients with germ cell cancer treated with Bleomycin, Etoposide, and Cisplatin. J Clin Oncol 34:1492PubMedCrossRef Lauritsen J et al (2016) Pulmonary function in patients with germ cell cancer treated with Bleomycin, Etoposide, and Cisplatin. J Clin Oncol 34:1492PubMedCrossRef
39.
Zurück zum Zitat Leenstra JL, Miller RC, Qin R et al (2014) Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]). J Clin Oncol 32:1571–1577PubMedPubMedCentralCrossRef Leenstra JL, Miller RC, Qin R et al (2014) Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]). J Clin Oncol 32:1571–1577PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, Awmf) (2017) Supportive Therapie bei onkologischen PatientInnen Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, Awmf) (2017) Supportive Therapie bei onkologischen PatientInnen
41.
Zurück zum Zitat Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, Awmf) (2019) S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, Awmf) (2019) S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens
43.
Zurück zum Zitat Ludwig H, Müldür E, Endler G et al (2013) Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 24:1886–1892PubMedPubMedCentralCrossRef Ludwig H, Müldür E, Endler G et al (2013) Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 24:1886–1892PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Mcguire DB, Fulton JS, Park J et al (2013) Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 21:3165–3177PubMedCrossRef Mcguire DB, Fulton JS, Park J et al (2013) Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 21:3165–3177PubMedCrossRef
45.
Zurück zum Zitat Meinardi MT, Gietema JA, van der Graaf WT et al (2000) Cardiovascular morbidity in long term survivors of metastatic testicular cancer. J Clin Oncol 18:1725–1732PubMedCrossRef Meinardi MT, Gietema JA, van der Graaf WT et al (2000) Cardiovascular morbidity in long term survivors of metastatic testicular cancer. J Clin Oncol 18:1725–1732PubMedCrossRef
47.
Zurück zum Zitat Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663PubMedCrossRef Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663PubMedCrossRef
48.
Zurück zum Zitat Necchi A, Miceli R, Oualla K et al (2017) Effect of bleomycin administration on the development of pulmonary toxicity in patients with metastatic germ cell tumors receiving first-line chemotherapy: a meta-analysis of randomized studies. Clin Genitourin Cancer 15:213–220.e5PubMedCrossRef Necchi A, Miceli R, Oualla K et al (2017) Effect of bleomycin administration on the development of pulmonary toxicity in patients with metastatic germ cell tumors receiving first-line chemotherapy: a meta-analysis of randomized studies. Clin Genitourin Cancer 15:213–220.e5PubMedCrossRef
49.
Zurück zum Zitat Nichols CR et al (1993) Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 85:36PubMedCrossRef Nichols CR et al (1993) Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 85:36PubMedCrossRef
50.
Zurück zum Zitat O’Sullivan JM et al (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14:91PubMedCrossRef O’Sullivan JM et al (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14:91PubMedCrossRef
51.
Zurück zum Zitat Ohlsson C, Wallaschofski H, Lunetta KL et al (2011) Genetic determinants of serum testosterone concentrations in men. PLoS Genet 7:e1002313PubMedPubMedCentralCrossRef Ohlsson C, Wallaschofski H, Lunetta KL et al (2011) Genetic determinants of serum testosterone concentrations in men. PLoS Genet 7:e1002313PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Pedrazzoli P, Farris A, Del Prete S et al (2008) Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 26:1619–1625PubMedCrossRef Pedrazzoli P, Farris A, Del Prete S et al (2008) Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 26:1619–1625PubMedCrossRef
53.
Zurück zum Zitat Piketty AC et al (2005) The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 93:909PubMedPubMedCentralCrossRef Piketty AC et al (2005) The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 93:909PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Pluschnig U, Haslik W, Bayer G et al (2015) Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol. Support Care Cancer 23:1741–1748PubMedCrossRef Pluschnig U, Haslik W, Bayer G et al (2015) Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol. Support Care Cancer 23:1741–1748PubMedCrossRef
55.
Zurück zum Zitat Poniatowska G et al (2020) What is the damage? Testicular germ cell tumour survivors deficient in testosterone at risk of metabolic syndrome and a need for medical intervention. Med Oncol 37:82–91PubMedCrossRef Poniatowska G et al (2020) What is the damage? Testicular germ cell tumour survivors deficient in testosterone at risk of metabolic syndrome and a need for medical intervention. Med Oncol 37:82–91PubMedCrossRef
56.
Zurück zum Zitat Rao RD, Michalak JC, Sloan JA et al (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110–2118PubMedCrossRef Rao RD, Michalak JC, Sloan JA et al (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110–2118PubMedCrossRef
57.
Zurück zum Zitat Raphael MJ, Logheed WX et al (2020) A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin. Curr Oncol 27(6):291–298PubMedPubMedCentralCrossRef Raphael MJ, Logheed WX et al (2020) A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin. Curr Oncol 27(6):291–298PubMedPubMedCentralCrossRef
59.
Zurück zum Zitat Seng S, Liu Z, Chiu SK et al (2012) Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and metaanalysis. J Clin Oncol 30:4416–4426PubMedCrossRef Seng S, Liu Z, Chiu SK et al (2012) Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and metaanalysis. J Clin Oncol 30:4416–4426PubMedCrossRef
60.
Zurück zum Zitat Seto BG, Kim M, Wolinsky L et al (1985) Oral mucositis in patients undergoing bone marrow transplantation. Oral Surg Oral Med Oral Pathol 60:493–497PubMedCrossRef Seto BG, Kim M, Wolinsky L et al (1985) Oral mucositis in patients undergoing bone marrow transplantation. Oral Surg Oral Med Oral Pathol 60:493–497PubMedCrossRef
61.
Zurück zum Zitat Smith AB et al (2016) The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. J Cancer Surviv 10:223PubMedCrossRef Smith AB et al (2016) The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. J Cancer Surviv 10:223PubMedCrossRef
62.
Zurück zum Zitat Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367PubMedPubMedCentralCrossRef Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Sprauten M, Darrah TH, Peterson DR et al (2012) Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol 30:300–307PubMedCrossRef Sprauten M, Darrah TH, Peterson DR et al (2012) Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol 30:300–307PubMedCrossRef
64.
Zurück zum Zitat Streckmann F, Zopf EM, Lehmann HC et al (2014) Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 44:1289–1304PubMedCrossRef Streckmann F, Zopf EM, Lehmann HC et al (2014) Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 44:1289–1304PubMedCrossRef
65.
Zurück zum Zitat Terbuch A, Posch F, Partl R et al (2018) Risk stratification for febrile neutropenia in patients with testicular germ cell tumors. Cancer Med 7:508–514PubMedPubMedCentralCrossRef Terbuch A, Posch F, Partl R et al (2018) Risk stratification for febrile neutropenia in patients with testicular germ cell tumors. Cancer Med 7:508–514PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Thorsen L et al (2017) Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer. J Clin Oncol 35:4551CrossRef Thorsen L et al (2017) Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer. J Clin Oncol 35:4551CrossRef
67.
Zurück zum Zitat Travis LB, Fossa SD, Schonfeld SJ et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97:1354–1365PubMedCrossRef Travis LB, Fossa SD, Schonfeld SJ et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97:1354–1365PubMedCrossRef
68.
Zurück zum Zitat Vehling S et al (2016) Anxiety and depression in long-term testicular germ cell tumor survivors. Gen Hosp Psychiatry 38:21PubMedCrossRef Vehling S et al (2016) Anxiety and depression in long-term testicular germ cell tumor survivors. Gen Hosp Psychiatry 38:21PubMedCrossRef
69.
Zurück zum Zitat Watson RA, De La Peña H, Tsakok MT et al (2018) Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK. Br J Cancer 119:1044–1051PubMedPubMedCentralCrossRef Watson RA, De La Peña H, Tsakok MT et al (2018) Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK. Br J Cancer 119:1044–1051PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat Willemse PM, Burggraaf J, Hamdy NAT et al (2013) Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer 109:60–67PubMedPubMedCentralCrossRef Willemse PM, Burggraaf J, Hamdy NAT et al (2013) Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer 109:60–67PubMedPubMedCentralCrossRef
71.
Zurück zum Zitat Yeap BB (2009) Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab 5:113–121PubMedCrossRef Yeap BB (2009) Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab 5:113–121PubMedCrossRef
72.
Zurück zum Zitat Cerchietti LC, Navigante AH, Körte MW et al (2003) Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain 105:265–273PubMedCrossRef Cerchietti LC, Navigante AH, Körte MW et al (2003) Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain 105:265–273PubMedCrossRef
73.
Zurück zum Zitat Fosså SD, Kaye SB, Mead GM et al (1998) Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 16:716–724PubMedCrossRef Fosså SD, Kaye SB, Mead GM et al (1998) Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 16:716–724PubMedCrossRef
74.
Zurück zum Zitat Lalla RV, Bowen J, Barasch A et al (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120:1453–1461PubMedCrossRef Lalla RV, Bowen J, Barasch A et al (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120:1453–1461PubMedCrossRef
Metadaten
Titel
Management von Nebenwirkungen der Chemotherapie und deren Langzeitfolgen
verfasst von
Dr. med. Isabella M. Zraik
Dr. med. Yasmine Heß-Busch
Publikationsdatum
28.06.2021
Verlag
Springer Medizin
Erschienen in
Die Urologie / Ausgabe 7/2021
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-021-01569-7

Weitere Artikel der Ausgabe 7/2021

Die Urologie 7/2021 Zur Ausgabe

Einführung zum Thema

Hodentumoren und Peniskarzinom

Termine

Termine

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.